Changes in regulations are reducing costs, expediting approval, and increasing the market for biosimilars.
Kimberly Salgado
Advertisement
Kimberly Salgado is Head of Centre for Biosimilar Drug Development, ICON plc
Articles by Kimberly Salgado
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Hold Times in Biopharmaceuticals
2
Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet
3
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
4
Merck KGaA Launches Saturnus Bio; Announces Awards
5